Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

598 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Meplazumab in hospitalized adults with severe COVID-19 (DEFLECT): a multicenter, seamless phase 2/3, randomized, third-party double-blind clinical trial.
Bian H, Chen L, Zheng ZH, Sun XX, Geng JJ, Chen R, Wang K, Yang X, Chen SR, Chen SY, Xie RH, Zhang K, Miao JL, Jia JF, Tang H, Liu SS, Shi HW, Yang Y, Chen XC, Malhotra V, Nasir N, Khanum I, Mahmood F, Hamid S, Stadnik CMB, Itinose K, de Oliveira CCC, Dusilek C, Rivabem L, Cavalcante AJW, Lopes SS, Saporito WF, Fucci FJC, Simon-Campos JA, Wang L, Liu LN, Wang QY, Wei D, Zhang Z, Chen ZN, Zhu P. Bian H, et al. Among authors: chen l, chen sr, chen zn, chen r, chen sy, chen xc. Signal Transduct Target Ther. 2023 Jan 30;8(1):46. doi: 10.1038/s41392-023-01323-9. Signal Transduct Target Ther. 2023. PMID: 36717539 Free PMC article. Clinical Trial.
Safety and efficacy of meplazumab in healthy volunteers and COVID-19 patients: a randomized phase 1 and an exploratory phase 2 trial.
Bian H, Zheng ZH, Wei D, Wen A, Zhang Z, Lian JQ, Kang WZ, Hao CQ, Wang J, Xie RH, Dong K, Xia JL, Miao JL, Kang W, Li G, Zhang D, Zhang M, Sun XX, Ding L, Zhang K, Jia J, Ding J, Li Z, Jia Y, Liu LN, Zhang Z, Gao ZW, Du H, Yao N, Wang Q, Wang K, Geng JJ, Wang B, Guo T, Chen R, Zhu YM, Wang LJ, He Q, Yao RR, Shi Y, Yang XM, Zhou JS, Ma YN, Wang YT, Liang X, Huo F, Wang Z, Zhang Y, Yang X, Zhang Y, Gao LH, Wang L, Chen XC, Tang H, Liu SS, Wang QY, Chen ZN, Zhu P. Bian H, et al. Among authors: chen zn, chen r, chen xc. Signal Transduct Target Ther. 2021 May 17;6(1):194. doi: 10.1038/s41392-021-00603-6. Signal Transduct Target Ther. 2021. PMID: 34001849 Free PMC article. Clinical Trial.
CD147 antibody specifically and effectively inhibits infection and cytokine storm of SARS-CoV-2 and its variants delta, alpha, beta, and gamma.
Geng J, Chen L, Yuan Y, Wang K, Wang Y, Qin C, Wu G, Chen R, Zhang Z, Wei D, Du P, Zhang J, Lin P, Zhang K, Deng Y, Xu K, Liu J, Sun X, Guo T, Yang X, Wu J, Jiang J, Li L, Zhang K, Wang Z, Zhang J, Yan Q, Zhu H, Zheng Z, Miao J, Fu X, Yang F, Chen X, Tang H, Zhang Y, Shi Y, Zhu Y, Pei Z, Huo F, Liang X, Wang Y, Wang Q, Xie W, Li Y, Shi M, Bian H, Zhu P, Chen ZN. Geng J, et al. Signal Transduct Target Ther. 2021 Sep 25;6(1):347. doi: 10.1038/s41392-021-00760-8. Signal Transduct Target Ther. 2021. PMID: 34564690 Free PMC article.
Efficacy and safety of GST-HG171 in adult patients with mild to moderate COVID-19: a randomised, double-blind, placebo-controlled phase 2/3 trial.
Lu H, Zhang G, Mao J, Chen X, Zhan Y, Lin L, Zhang T, Tang Y, Lin F, Zhu F, Lin Y, Zeng Y, Zhang K, Yuan W, Liang Z, Sun R, Huo L, Hu P, Lin Y, Zhuang X, Wei Z, Chen X, Yan W, Yan X, Mu L, Lin Z, Tu X, Tan H, Huang F, Hu Z, Li H, Li G, Fu H, Yang Z, Chen X, Wang FS, Zhong N. Lu H, et al. EClinicalMedicine. 2024 Apr 10;71:102582. doi: 10.1016/j.eclinm.2024.102582. eCollection 2024 May. EClinicalMedicine. 2024. PMID: 38618202 Free PMC article.
De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial.
Chen XC, Jiao DC, Qiao JH, Wang CZ, Sun XF, Lu ZD, Li LF, Zhang CJ, Yan M, Wei Y, Chen B, Feng YQ, Deng M, Ma MD, Plichta JK, He YW, Liu ZZ. Chen XC, et al. Lancet Oncol. 2024 Nov 26:S1470-2045(24)00581-3. doi: 10.1016/S1470-2045(24)00581-3. Online ahead of print. Lancet Oncol. 2024. PMID: 39612919
A large-scale population-based study reveals that gp42-IgG antibody is protective against Epstein-Barr virus-associated nasopharyngeal carcinoma.
Kong XW, Bu GL, Chen H, Huang YH, Liu Z, Kang YF, Li YC, Yu X, Wu BH, Li ZQ, Chen XC, Xie SH, Lin DF, Li T, Yan SM, Han RK, Huang N, Wang QY, Li Y, Zhang A, Zhong Q, Huang XM, Ye W, Ji MF, Cai YL, Cao SM, Zeng MS. Kong XW, et al. Among authors: chen xc. J Clin Invest. 2024 Nov 26:e180216. doi: 10.1172/JCI180216. Online ahead of print. J Clin Invest. 2024. PMID: 39589824 Free article.
598 results